Deep Intelligence Across Industries

The Estée Lauder Companies is the world's largest pure-play prestige beauty house. It owns a portfolio of more than 20 luxury and prestige brands, including Estée Lauder, Clinique, M·A·C, La Mer, Jo Malone London, TOM FORD, Le Labo and The Ordinary, sold in about 150 countries. Skin care (about 49% of FY2026 sales) anchors the profit pool, and luxury fragrance is now the fastest-growing engine. FY2023–FY2025 were three years of decline. Over-exposure to Chinese consumers and Asia travel retail unwound, the company took $1.3B of impairments, and it posted a $1.1B net loss in FY2025. FY2026 was the first year of the "Beauty Reimagined" turnaround under CEO Stéphane de La Faverie: organic sales rose 3% and adjusted operating margin expanded 320bp to 11.2%. The investment case now depends on restoring scale growth in North America, sustaining China share gains, and converting $1.2B of restructuring benefits into a "solid double-digit" margin. Family control (82% of votes) limits governance optionality. The abandoned Puig merger in 2026 showed the board is willing to consider transformative M&A. --- **Company's own description (10-K FY2026, paraphrased).** The company describes itself as one of the world's leading manufacturers, marketers and sellers of quality skin care, makeup, fragrance and hair care products, and as a steward of more than 20 luxury and prestige brands. It operates mainly as a wholesaler. Its products are sold in physical stores and on e-commerce platforms run by department stores, duty-free retailers, specialty-multi retailers, online pure players, perfumeries and pharmacies, and salons and spas. It also runs a direct-to-consumer business through freestanding stores, brand websites and third-party online platforms. Since February 2025 its strategic vision has been "Beauty Reimagined", executed through the "One ELC" operating model. **Independent characterization.** EL is a brand-portfolio owner and marketer that is vertically integrated into formulation and manufacturing. It sits at the top of the beauty value chain: - It controls R&D, brand equity and most manufacturing. It has its own plants in the US, Canada, Belgium, Switzerland, the UK and Japan, plus third-party manufacturers. - Downstream it relies heavily on retail partners. Its revenue model is about 99% product sales. Royalty income, mainly from licensing the TOM FORD fashion and eyewear trademark, sits in "Other" (about $103M in FY2026, 0.7% of sales). There is no meaningful subscription or service revenue. - Price architecture runs from accessible-prestige (The Ordinary) to ultra-luxury (La Mer, TOM FORD Private Blend, Frédéric Malle). **Customer types.** - Retail customers (B2B): department stores such as Macy's, Nordstrom and Harrods; specialty-multi retailers such as Sephora, Ulta and Douglas; duty-free operators in Hainan, Korea and Hong Kong; e-commerce platforms such as Tmall, JD.com and Amazon Premium Beauty; TikTok Shop; perfumeries and pharmacies; and salons (Aveda, Bumble and bumble). - End consumers (B2C) through freestanding stores and brand.com sites. - Licensees (TOM FORD fashion and eyewear), which generate royalty income. **End-markets.** The company serves global prestige skin care, color cosmetics, fine fragrance (including the fast-growing "artisanal/niche" luxury tier) and professional or prestige hair care. - By geography, about 26% of FY2025 net sales were in the US and 74% international (FY2025 Fact Sheet). - Mainland China alone was $3.06B, or 20% of FY2026 net sales. - Travel retail, now reported inside Asia/Pacific, was about 15% of reported sales in FY2025, down sharply from its pandemic-era peak (BeautyMatter, FY2025 call). **Seasonality.** First-half (July–December) sales are typically slightly higher than the second half because of holiday and key shopping events such as 11.11 and 6.18 in China (10-K FY2026).

Sappi is a mid-sized, vertically integrated woodfibre group with operations on three continents and sales into more than 150 countries. Its earnings rest on two structurally different engines. The first is a globally significant dissolving wood pulp (DWP) franchise, Verve, based in South Africa and Cloquet (US), backed by company-owned plantations; in FY2025 it generated 46% of group Adjusted EBITDA from 29% of volumes. The second is a portfolio of graphic, packaging and speciality papers in Europe and North America. Since 2021 management has pursued a portfolio pivot: shrinking European graphic paper through closures and now a 50/50 joint venture with UPM, and redeploying capital into US solid bleached sulphate (SBS) paperboard through the US$418m Somerset PM2 conversion. The investment cycle peaked into a severe pricing downturn. As a result, Sappi enters FY2027 highly levered (6.5x net debt/Adjusted EBITDA at June 2026), with covenant testing suspended to March 2027 and a regulatory-dependent restructuring of Europe pending. --- **Company's own description.** The latest reporting describes the group in one line: "Sappi uses renewable resources to make woodfibre-based products." [S4, FY2026]. Management further describes Sappi as a diversified, innovative and trusted leader making pulp, packaging and speciality papers, graphic papers and biomaterials from woodfibre sourced from sustainably managed forests. Many mills are energy self-sufficient through internally generated bioenergy [S4]. **What the company does.** Sappi converts wood (largely its own plantation fibre in South Africa, plus purchased wood in Europe and North America) into three main product families: 1. **Pulp.** This comprises dissolving wood pulp sold mainly to viscose staple fibre (VSF) and other cellulose-derivative producers (textiles, plus pharmaceutical and food applications), together with paper-grade and high-yield pulp (BCTMP) used internally or sold externally [S3][S9]. 2. **Packaging and speciality papers (P&SP).** This includes SBS/solid bleached board paperboard, label papers, flexible packaging papers, release papers (casting/release for synthetic leather and laminates), containerboard (South Africa), tissue and technical papers [S3][S9]. 3. **Graphic papers.** These are coated woodfree, coated mechanical, uncoated woodfree office paper and newsprint [S3][S9]. Biomaterials (nanocellulose, lignin, xylose, furfural) and forestry/timber sales round out the portfolio [S9]. **Business model.** The model is overwhelmingly product sales. There is no material service, subscription or licensing revenue disclosed. Revenue is booked on delivery of tonnes. Since FY2025, revenue has been presented net of delivery costs where Sappi acts as agent for shipping; FY2024 was restated accordingly [S3]. **Value-chain position.** Sappi is upstream-integrated from forest to pulp to paper in South Africa, with 401,000 ha owned or leased, of which 262,000 ha is planted [S9; date of figure not stated]. It is partially integrated in North America (Cloquet pulp to graphic paper; Matane BCTMP to Somerset board) and in Europe (Ehingen, Gratkorn and Kirkniemi pulp lines). It sells mainly B2B to converters, printers, merchants, VSF/textile mills, label converters, packaging converters and brand owners. **Independent characterisation.** Despite revenue still being about 44% graphic paper, Sappi should be analysed as a DWP-and-packaging group carrying a large, declining graphic-paper tail. The economics are highly asymmetric: **Pulp:** is the profit engine: 46% of FY2025 Adjusted EBITDA from 29% of volumes [Sappi investor page, FY2025]. **P&SP:** has absorbed most recent capital but delivered only 13% of FY2025 Adjusted EBITDA from 30% of volumes. In 9M FY2026 its Adjusted EBITDA was slightly negative [S3][S4]. **Graphic paper:** remains cash-generative in North America, where supply is tight after the PM2 conversion and import tariffs. It is structurally loss-prone in Europe [S3][S4]. **Value drivers to watch:** the CCF hardwood DWP price in China, the ZAR/US$ exchange rate, which drives South African margins and plantation valuations, and NA SBS paperboard pricing. **Customer types and end-markets:** - Textile and nonwoven fibre producers (VSF, lyocell), mainly in Asia - Food, beverage, cosmetics and pharma brand owners (via label and packaging converters) - Commercial printers, publishers and catalogue/magazine producers - Office paper distributors and newspaper publishers (South Africa) - Agricultural exporters (citrus containerboard in South Africa) - Automotive, fashion and decorative-laminate producers (release paper) - Industrial users of lignin and biochemicals

NIKE, Inc. is the world's largest designer, marketer and distributor of athletic footwear, apparel and equipment, operating three brands — NIKE, Jordan and Converse — across substantially every country on earth through a hybrid model of wholesale distribution and owned direct-to-consumer channels. It is an asset-light brand company: nearly all product is made by independent contract manufacturers concentrated in Vietnam, Indonesia, China and Cambodia, while NIKE retains design, innovation, marketing, demand creation and marketplace control. Its competitive position rests on the most valuable trademark portfolio in sport, unmatched athlete and league endorsement infrastructure, and scale economics that no competitor approaches. As of FY2026 the company is mid-way through the most significant strategic reset in two decades: a shift back from a digitally-led direct model toward an integrated, wholesale-inclusive marketplace, and a reorganisation from consumer-gender categories to vertically-integrated sport teams under an operating model management calls "Sport Offense." Revenue has been flat to declining for three years and the equity has de-rated severely. *FY2024 headcount of approximately 79,400 is the figure disclosed in NIKE's FY2024 Form 10-K and widely cited thereafter. The FY2026 figure of approximately 73,000 is stated directly in the FY2026 Form 10-K.* --- ## The company's own description In the FY2026 Form 10-K, NIKE describes its principal business activity as the design, development and worldwide marketing and selling of athletic footwear, apparel, equipment, accessories and services, and states plainly that it is the largest seller of athletic footwear and apparel in the world. It sells through NIKE Direct operations — comprising NIKE-owned retail stores and digital platforms referred to as NIKE Brand Digital — and to wholesale accounts including independent distributors, licensees and sales representatives in nearly all countries. It also offers interactive consumer services and experiences. Nearly all products are manufactured by independent contractors, and nearly all footwear, apparel and equipment is manufactured outside the United States. The 10-K articulates the strategy as achieving sustainable, profitable long-term growth by leading with sport, creating innovative "must-have" products, building deep personal consumer connections with the brands, and delivering compelling consumer experiences through digital platforms and at retail. ## Independent characterisation NIKE is best understood as three overlapping businesses operating under one balance sheet. **First, a branded product design and licensing engine.** The economic core of NIKE is not manufacturing — it owns almost no finished-goods factories — but the ownership and continuous refreshment of trademarks (NIKE, Swoosh, Jumpman, Air Max, Chuck Taylor) and the technology platforms (Air, Zoom, ZoomX, Flyknit, Dri-FIT, React, FlyEase) that justify a price premium over commodity footwear. Gross margin of 42.9% in FY2026 is the visible output of this: the difference between contract-manufactured cost and brand-supported retail price. **Second, a wholesale distribution business.** In FY2026, wholesale revenue was 27.5 billion USD, approximately 59% of total company revenue, and grew 6% reported / 4% currency-neutral even as the total shrank. This is the channel NIKE deliberately de-emphasised between 2017 and 2023 and has spent the last two fiscal years rebuilding. It is lower-gross-margin but lower-fixed-cost and lower-working-capital than direct retail. **Third, an owned retail and digital business.** NIKE Direct generated 17.7 billion USD in FY2026 (approximately 38% of total revenue), split between NIKE Brand Digital at 8.6 billion USD and NIKE-owned stores at 9.1 billion USD. This is the part of the business in structural retreat: digital fell 12% and comparable store sales fell 4% in FY2026. It carries high fixed costs — leases, store labour, technology platforms — which is why its decline is disproportionately painful to operating leverage. ## Revenue model composition | Revenue stream (USD M) | FY2024 | FY2025 | FY2026 | |---|---|---|---| | Wholesale (NIKE Brand) | n/d | 25943 | 27500 | | NIKE Direct total | n/d | 18800 | 17700 | | NIKE Brand Digital | n/d | 9600 | 8600 | | NIKE-owned stores | n/d | 9200 | 9100 | | Global Brand Divisions (licensing and other) | 45 | 48 | 49 | | Converse | 2082 | 1692 | 1174 | NIKE is overwhelmingly a product company. There is no meaningful subscription revenue line. Licensing and miscellaneous non-geographic revenue is reported within "Global Brand Divisions" and totalled just 49 million USD in FY2026 — a rounding error at 0.1% of revenue — although this understates the economic role of licensing, since licensed team and league apparel sold by NIKE itself is booked in the geographic segments. *FY2025 wholesale of approximately 25.9 billion USD is derived from the FY2026 disclosure that wholesale grew 6% on a reported basis to 27.5 billion USD; NIKE Direct FY2025 of 18.8 billion USD is stated directly in the FY2026 10-K MD&A. FY2024 channel splits are not restated in the FY2026 filing and are marked n/d.* ## Value chain position and customer types NIKE occupies the design–brand–marketing tier of the athletic goods value chain and outsources both upstream materials conversion and a majority of downstream physical retail. Its direct customers fall into four groups: (i) large multi-brand athletic retailers (Foot Locker, JD Sports, Dick's Sporting Goods and equivalents); (ii) department and specialty stores; (iii) international independent distributors and licensees in markets where NIKE does not operate directly; and (iv) end consumers via NIKE Direct. In FY2026, no single customer accounted for 10% or more of consolidated revenues, but NIKE's three largest U.S. customers accounted for approximately 29% of U.S. sales, and its three largest non-U.S. customers accounted for approximately 16% of non-U.S. sales — a meaningful concentration that has increased as retail has consolidated. ## End markets Performance athletic footwear and apparel (running, basketball, global football, training, tennis, golf, skateboarding, outdoor/ACG); lifestyle and streetwear derived from athletic heritage (Sportswear, Jordan streetwear, Converse); and licensed team/league apparel. Geographically the business is roughly 44% United States and 56% international by revenue in FY2026 — a U.S. weighting that has risen for two consecutive years as international, and particularly Greater China, has contracted.

IFF is one of the world's "big four" flavour-and-fragrance houses and, following the 2021 merger with DuPont Nutrition & Biosciences, the broadest specialty-ingredients platform in consumer goods. The company is now in the final phase of a multi-year portfolio simplification: having divested 13 non-core businesses for roughly US$10bn of gross proceeds, it agreed in May 2026 to sell its largest and lowest-margin unit, Food Ingredients, to CVC Capital Partners for an enterprise value of ~US$4.3bn. The go-forward company comprises three innovation-led segments — Taste, Scent and Health & Biosciences — guided to ~US$7.4–7.6bn of 2026 sales at a ~21% adjusted operating EBITDA margin, with leading positions in flavours, fine and consumer fragrance, enzymes, cultures and probiotics. The investment debate centres on whether the slimmer, higher-margin IFF can re-rate towards Givaudan-like multiples once deleveraging, a US$2.5bn buyback and resolution of the global fragrance antitrust investigations are delivered. --- ### What the company does IFF designs, manufactures and sells proprietary ingredient systems that determine how consumer products taste, smell, feel and perform. Its products are almost never visible to the end consumer: they are formulated into customers' beverages, dairy products, snacks, savoury foods, sweets, dietary supplements, perfumes, detergents, shampoos, home-care products, animal feed, biofuels and industrial processes. The company's own boilerplate (2026) describes IFF as a business that "makes joy through science, creativity and heart" and positions itself as the global leader in flavours, fragrances, and health and biosciences — a description that, notably, dropped the words "food ingredients" between the February 2026 and August 2026 releases, mirroring the decision to divest that segment. ### Business model **Co-creation and formulation model (Taste, Scent):** IFF wins "briefs" from consumer-goods customers and creates bespoke, confidential formulas (flavour compounds, fragrance compounds). Once a formula is adopted into a customer's product it typically remains for the product's lifecycle, producing recurring, annuity-like revenue. Switching costs are high because reformulation risks consumer rejection. Many large customers operate "core lists" of a small number of approved suppliers, which is a structural barrier to entry. **Science-platform model (Health & Biosciences):** Revenue derives from proprietary enzymes, cultures, probiotics and biotech-derived ingredients produced through fermentation. Value is underpinned by strain libraries, protein-engineering IP and large-scale fermentation capacity (the DuPont/Genencor/Danisco heritage). - **Ingredient-supply model (Fragrance Ingredients and, until divested, Food Ingredients).** More volume-driven, partly commodity-exposed businesses (aroma chemicals; texturants, emulsifiers, plant proteins). ### Revenue model mix | Revenue type | Estimated share | Basis | |---|---|---| | Product sales (compounds, ingredients, enzymes, cultures) | ~100% | 10-K revenue recognition; services embedded | | Services billed separately | Not material / not publicly disclosed | — | | Licensing / royalties | Not material / not publicly disclosed | — | IFF is overwhelmingly a product company: revenue is recognised on shipment of physical ingredients. Formulation, sensory and application services are bundled into product pricing rather than billed separately. There is no material subscription or licensing revenue disclosed. A small portion of H&B revenue derives from technology collaborations, but this is not separately quantified (not publicly disclosed). ### Value-chain position IFF sits in the middle of the chain: upstream it buys natural raw materials (citrus oils, vanilla, botanicals, crude sulphate turpentine, petrochemical intermediates, agricultural commodities, sugars for fermentation) and downstream it sells to brand owners and contract manufacturers. Value capture comes from formulation know-how, regulatory dossiers, application labs and fermentation IP rather than from raw-material processing. ### Customer types and end-markets | Customer type | Examples of end use | Primary IFF segment | |---|---|---| | Global food & beverage multinationals | Soft drinks, dairy, savoury, sweet goods | Taste; (Food Ingredients — divesting) | | Regional/local food & beverage manufacturers | Local beverages, bakery, snacks | Taste | | Fine-fragrance houses and luxury/prestige brands | Perfumes, eau de toilette | Scent (Fine Fragrance) | | Home & personal-care multinationals | Detergents, fabric care, shampoo, soap | Scent (Consumer Fragrance); H&B (Home & Personal Care enzymes) | | Dietary-supplement and infant-nutrition companies | Probiotics, HMOs | H&B (Health) | | Animal-nutrition and feed producers | Feed enzymes (phytase), probiotics | H&B (Animal Nutrition) | | Grain processors and biofuel producers | Ethanol, starch, sweetener processing | H&B (Grain Processing) | | Pharmaceutical manufacturers | Excipients (until 2025 disposal) | Pharma Solutions (divested May 2025) | ### Independent characterisation IFF is best understood today as a company in transition from a sprawling, leverage-burdened conglomerate (post-Frutarom and DuPont N&B) to a focused "taste-scent-biosciences" pure play. On a continuing-operations basis it generated a 21.8% adjusted operating EBITDA margin in H1 2026, versus 19.2% for the full 2025 portfolio — the arithmetic of the portfolio change is margin-accretive, but the company will be roughly one-third smaller by revenue than it was in 2024. Its closest strategic analogue is Givaudan, which has historically commanded a significant valuation premium; the core thesis of the turnaround is closing that gap.

Kerry Group is a global business-to-business taste and nutrition partner to the food, beverage and pharmaceutical industries, and since the 31 December 2024 divestment of Kerry Dairy Ireland it has operated as a pure-play ingredients and solutions company. It combines a broad technology toolkit — savoury and sweet taste, Tastesense™ salt and sugar reduction, botanicals and natural extracts, enzymes, probiotics and other bio-fermented ingredients, clean-label food protection and preservation, proteins, emulsifiers and texturants, and pharma excipients and cell nutrition — with deep application know-how and a network of customer innovation centres. Kerry positions itself as its customers' innovation and "renovation" partner, helping brand owners, retailers' private labels and foodservice chains improve taste, nutrition, cost and sustainability. FY2025 revenue was €6.76bn with an EBITDA margin of 17.9%; roughly 54% of revenue is in the Americas, a third comes from emerging markets, and about a third flows through the foodservice channel. Management's 2030 framework targets 3–5% volume growth and a 20–21% EBITDA margin. --- **Company's own description (paraphrased from the H1 2026 report, Note 2).** Kerry describes its three operating segments (Europe, Americas, APMEA) as leading providers of taste and nutrition solutions for food, beverage and pharmaceutical markets. It uses a broad range of ingredient solutions to co-innovate with customers, aiming to create great-tasting products with improved nutrition and functionality while reducing environmental impact. Its stated purpose is to be its customers' most valued partner in creating a world of sustainable nutrition. **What Kerry does.** Kerry sells formulated ingredient systems and single-technology ingredients to food and beverage manufacturers, quick-service restaurant (QSR) and coffee chains, convenience retailers, retailers' own-label programmes, supplement makers and pharmaceutical/biopharma producers. The economic unit is rarely a commodity: Kerry typically co-develops a seasoning system, a coating, a flavour, a beverage base, a preservation system or an enzyme solution against a customer brief, then becomes the specified supplier when the customer launches or reformulates. This "innovation and renovation" model creates stickiness, because switching a specified ingredient requires reformulation, sensory re-validation and often regulatory re-labelling. **Revenue model.** Revenue is overwhelmingly product revenue recognised at a point in time (H1 2026 report: revenue recognised over time was not material). There is no material subscription or licensing revenue; technical services, application development and co-creation are bundled into product pricing. Pricing is largely cost-pass-through with a lag — visible in 2024–2026 when input-cost deflation drove negative pricing (FY2025: −0.3%; H1 2026: −1.0%) while margins expanded. **End-use markets (EUMs).** Kerry discloses revenue by three top-level EUMs and discusses sub-EUMs (Snacks, Meat, Meals, Dairy, Bakery, Beverage, Pharma & other). *Source: H1 2026 Interim Report, Note 2 (FY2025 audited comparatives).* **Customer types.** Global and regional CPG manufacturers (snacks, meat and poultry processors, dairy, bakery, beverages), retailers' private labels, global and regional QSR and coffee chains, emerging foodservice operators, supplement brands, pharma (oral solid dose excipients, tablet coatings) and biopharma (cell culture nutrition). Kerry states there is no customer concentration requiring IFRS 8 disclosure (H1 2026 report). **Value-chain position.** Kerry sits between agricultural/chemical raw-material suppliers (dairy, grains, spices, botanicals, coffee, sugars, fermentation feedstocks) and branded/foodservice customers. It adds value through formulation IP, sensory science, process technologies (spray-drying, extrusion, fermentation, extraction, smoke condensates, enzymatic modification) and regulatory support. **Independent characterisation.** Kerry is best understood as a mid-teens-to-high-teens EBITDA-margin "solutions" business with a heavier exposure to savoury taste, meat/snack systems and foodservice than the classic flavour houses (Givaudan, Symrise, IFF, dsm-firmenich), and a lower margin than those peers because a larger share of its revenue is formulated bulk systems rather than concentrated flavours. The 2021–2025 portfolio reshaping (sale of consumer foods 2021, Sweet Ingredients Portfolio 2023/24, Dairy Ireland 2024; purchases in preservation, enzymes, probiotics and botanicals) was a deliberate migration up the value curve, visible in the EBITDA margin moving from 14.6% (FY2021, incl. dairy) to 17.9% (FY2025) and a 2030 target of 20–21%. The main analytic tension is that reported revenue has been shrinking (portfolio exits, price deflation, FX) even as volumes grow c.3% per year.

ITC Limited is India's most structurally unusual large-cap consumer company: a 116-year-old enterprise whose cash engine is the country's dominant legal cigarette franchise, and whose growth engine is a self-built, 30-plus-brand branded-packaged-goods portfolio now generating more than INR 37,000 crore of annual consumer spend across roughly 280 million Indian households. Around it sit two industrial businesses — an integrated paperboards and specialty papers operation, enlarged in August 2026 to become India's largest, and an agri-commodity sourcing and value-added agri-products business that doubles as the procurement backbone for the FMCG portfolio — plus a wholly owned IT services arm, ITC Infotech, now being combined with Happiest Minds and separately listed. Following the January 2025 demerger of ITC Hotels, ITC is a four-segment company. Its central investment question is whether non-cigarette earnings can compound fast enough to offset a cigarette business facing the steepest tax escalation in two decades. *Zeros denote "not available from that source for that year," not a nil value.* The two series measure different populations: ITC's own Report & Accounts headcount covers ITC Limited standalone permanent employees, while third-party workforce-intelligence estimates capture the extended group including subsidiaries and contract populations. A third aggregator (LeadIQ) cites approximately 60,000 as at March 2026. The company's own annual-report figure (circa 22,000–22,500 standalone) should be treated as authoritative for ITC Limited; the ~55,000–60,000 figures should be read as group-wide/extended estimates. --- ### What the company does ITC operates four reported segments plus a portfolio of group companies. In the company's own framing from its FY2026 disclosures, its operating architecture rests on what it calls "institutional strengths": consumer insight, a distributed manufacturing and omni-channel distribution architecture, the research capability of its Life Sciences and Technology Centre (LSTC), agri-sourcing depth, and cuisine expertise resident in group entity ITC Hotels Limited. **FMCG–Cigarettes.** ITC is the dominant player in India's legal cigarette industry, operating what it describes as an integrated "seed-to-smoke" value chain — leaf tobacco development and sourcing through the Agri Business, green leaf threshing, manufacturing, in-house packaging and printing, and a proprietary distribution network. Principal trademarks include Classic, Gold Flake, American Club, Navy Cut, Players, Capstan and Bristol. **FMCG–Others.** The non-cigarette consumer portfolio spans Branded Packaged Foods (staples, biscuits, snacks, noodles, dairy, frozen foods, spices, beverages, confectionery), Personal Care Products (personal wash, fragrances, health & hygiene, home care), Education & Stationery Products, and Incense Sticks (Agarbattis) & Safety Matches. **Agri Business.** Two sub-businesses: (i) Indian Leaf Tobacco, where ITC states it is the largest Indian exporter of unmanufactured tobacco; and (ii) Other Agri Commodities, comprising wheat, spices, coffee, frozen marine products, processed fruits and vegetables, increasingly organised around a Value-Added Agri Products (VAAP) strategy. The segment also runs ITCMAARS, a crop-agnostic "phygital" full-stack agritech platform. **Paperboards, Paper & Packaging.** Integrated paperboards and specialty papers manufacture (value-added paperboards, eco-labelled and premium recycled grades, décor paper) plus a Packaging & Printing business serving food & beverage, personal care, home care, footwear, consumer electronics, QSR, pharma, liquor and tobacco customers. **Group companies (consolidated, not separately reported segments at the ITC level).** ITC Infotech India Limited (IT and business solutions), Surya Nepal Private Limited (cigarettes, matches and apparel in Nepal), ITC IndiVision Limited (nicotine and nicotine-derivative manufacture and export), Sproutlife Foods Private Limited (Yoga Bar; subsidiary from 1 April 2026), Ample Foods Private Limited (Prasuma, Meatigo; associate), and a 40% stake in listed ITC Hotels Limited. ### Business and revenue model ITC is overwhelmingly a product business. Revenue is recognised on the sale of physical goods — cigarettes, packaged foods, personal care products, notebooks, paperboard, agri-commodities. There is effectively no subscription revenue at the ITC Limited level. Licensing revenue exists but is immaterial at the parent; the principal licensing/asset-light model in the group sits inside ITC Hotels (a 40%-held associate, not consolidated). Services revenue arises through ITC Infotech (IT services, project- and time-and-materials-based) and, in nascent form, through the Fresh Food cloud-kitchen business, which is a product-plus-delivery model transacted through third-party aggregator platforms. Independent characterisation of the economic engine: ITC runs a high-margin, low-growth cash generator (cigarettes) funding a mid-margin, high-growth compounder (FMCG–Others), hedged by a low-margin, high-turnover commodity business (Agri) that is strategically valuable less for its own profit pool than for the sourcing advantage, farmer linkage and raw-material security it confers on Foods and Cigarettes, and anchored by a cyclical industrial business (Paperboards) that supplies internal packaging demand and provides a plastic-substitution growth option. ### Value-chain position and customers ITC sits unusually far up and down the chain simultaneously. Upstream it engages directly with farmers — the FY2026 disclosures record over 2,100 Farmer Producer Organisations and approximately 2.3 million farmers on the ITCMAARS network, with roughly 40% of the wheat used for Aashirvaad Atta and the Agri Business now sourced directly from FPOs. Midstream it manufactures at scale, including 12 operational Integrated Consumer Goods Manufacturing and Logistics facilities (ICMLs) and Ancillary Manufacturing cum Logistics Facilities (AMLFs) at Pudukkottai and Kapurthala. Downstream it operates one of India's deepest general-trade distribution systems, digitally enabled by the UNNATI eB2B platform covering more than 800,000 outlets, alongside rapidly scaling NewGen channels. Customer types: (i) Indian retail consumers via general trade, modern trade, e-commerce and quick commerce; (ii) B2B industrial customers for paperboard and packaging; (iii) international leaf tobacco buyers (global cigarette manufacturers); (iv) international agri-commodity buyers across Europe, the Middle East and elsewhere; (v) enterprise clients of ITC Infotech. A structurally important disclosure from FY2026: digitally enabled sales together with Modern Trade now account for 34% of the company's Branded Packaged Foods, Personal Care Products, Incense Sticks and Safety Matches sales — a channel-mix shift that materially changes ITC's historic general-trade-dependent competitive moat.

Kao Corporation is Japan's largest household and personal-care manufacturer and a vertically integrated oleochemical producer. Its 139-year heritage in interface science underpins both its consumer brands and its industrial chemicals. The group generated ¥1,688.6bn of net sales and ¥164.1bn of operating income in FY2025. About 57% of sales come from Japan, where Kao holds category-leading positions in laundry (Attack), dishwashing (Kyukyutto), sanitary products (Laurier, Merries), skin care (Bioré, Curél) and prestige cosmetics (Kanebo, Sofina, SENSAI, KATE). Outside Japan, Kao competes in Asia, the Americas and EMEA through acquired Western brands (Jergens, John Frieda, Goldwell, Molton Brown, Oribe, Bondi Sands) and through a ¥405bn chemicals franchise. That chemicals business supplies fatty alcohols, surfactants, semiconductor and HDD process chemicals, and inkjet colourants. Under the "K27" mid-term plan, Kao is recovering from its 2023 profit trough. It is targeting record operating income (above ¥211.7bn), ROIC of at least 11% and ¥800bn of overseas sales by 2027. Execution has been credible, while governance and supply-chain scrutiny from activist Oasis Management remains active. --- ### What the company does Kao manufactures and markets branded consumer products and industrial chemicals. Since the FY2025 re-segmentation it reports two business groups and five segments. **Global Consumer Care (GCC)** — ¥1,283.0bn of sales in FY2025 (76.0% of the group). It has four segments: **Hygiene & Living Care:** fabric care, home care and sanitary products. **Health & Beauty Care:** skin care, hair care and related products. **Cosmetics:** prestige and masstige make-up and skin care. **Business Connected:** professional-use hygiene and co-created B2B solutions; formerly the core of the "Life Care" segment. **Chemical Business** — ¥405.7bn of sales in FY2025 (24.0%). It covers oleochemicals, performance chemicals, specialty and information materials, and aroma chemicals. ### Company's own description Kao describes itself as a comprehensive consumer products and chemicals manufacturer. It says it is pursuing a "Global Sharp Top" strategy: becoming "a unique presence indispensable to someone in the world" by concentrating on businesses with high unmet needs, high profitability and global scalability (Kao Integrated Report 2025; K27 materials). Kao frames its portfolio in three strategic layers: **Stable Earnings:** Hygiene & Living Care, largely in Japan. **Growth Drivers:** skin protection, focus cosmetics brands, premium hair care and high-value chemicals. **Business Transformation:** under-performing or restructuring businesses. ### Revenue model | Revenue type | Share (FY2025, est. from segment mix) | Comment | |---|---|---| | Branded consumer product sales (B2C via retail) | ~73–74% | Drugstores, GMS/supermarkets, e-commerce and department stores (cosmetics) in Japan. Modern trade and e-commerce in Asia. Mass and specialty retail in the US/EU | | Professional / B2B consumer-adjacent products | ~2.3% | Business Connected: hygiene for hospitals, restaurants and facilities | | Salon / professional hair care | Within HBC | Goldwell, KMS and Oribe, sold through salons and distributors in the Americas and EMEA | | Industrial chemical sales (B2B) | ~24% | Contract and spot sales to industrial customers. Partly priced off raw-material indices (palm kernel oil, coconut oil, petrochemicals) with lagged pass-through | | Subscription / licensing | Not material | No disclosed licensing or subscription revenue lines | ### Value-chain position Kao is unusual among global FMCG peers in being backward-integrated into oleochemicals. It operates fatty-alcohol and fatty-acid production in Malaysia (Fatty Chemical (Malaysia) Sdn. Bhd.), the Philippines (Pilipinas Kao), Indonesia and Spain. These units feed its own surfactant needs and also sell externally. This integration gives Kao cost and technology advantages in surfactants. ### Customer types and end markets | Customer type | End market | Representative brands / products | |---|---|---| | Households (mass) | Laundry, dishwashing, cleaning, diapers, feminine care | Attack, Humming, Kyukyutto, Magiclean, Quickle, Merries, Laurier | | Individual consumers (beauty / personal care) | Skin care, sun care, hair care, body care, oral, bath | Bioré, Curél, Jergens, Bondi Sands, Segreta, Essential, Merit, Liese, melt, THE ANSWER, John Frieda, Guhl, bub, Ban | | Prestige beauty consumers | Cosmetics, luxury skin care, fragrance | Kanebo, SENSAI, Sofina iP, KATE, Molton Brown, est, RMK, SUQQU, freeplus | | Salons / stylists | Professional hair colour and care | Goldwell, KMS, Oribe | | Hospitals, food service, institutions | Professional hygiene | Kao Professional Services products | | Industrial customers | Personal-care and detergent manufacturers, plastics, construction, printing, electronics/semiconductors, HDD makers, fragrance | Fatty alcohols and amines, surfactants, concrete admixtures, asphalt modifiers, toner binders, inkjet colourants, semiconductor cleaning agents, HDD substrate polishing agents, aroma chemicals | ### Independent characterisation Kao is best understood as a Japan-centric household-products cash engine bolted to two option-value businesses: a turnaround-stage global cosmetics portfolio and a cyclical but technologically differentiated oleo/specialty-chemicals arm. The stable core (Hygiene & Living Care, 14.8% operating margin in FY2025) funds reinvestment. The investment case therefore depends on whether cosmetics and overseas consumer care can scale to K27 targets without diluting returns. Its ROIC-led capital discipline, introduced in August 2023, has been effective. Group operating margin has recovered from 3.9% (FY2023) to 9.7% (FY2025) and ~11% on a TTM basis by mid-2026.

Amorepacific Corporation is South Korea's largest pure-play beauty company and the operating core of the Amorepacific group. It owns a multi-brand portfolio spanning luxury (Sulwhasoo, HERA, AP Beauty), premium (LANEIGE, IOPE, Mamonde, Hanyul, Primera), derma (AESTURA, ILLIYOON, COSRX), hair care (RYO, Mise-en-Scène, LABO-H) and body/oral care. After a decade of China-led expansion and a painful post-2016 reset, the company spent 2023–2026 rebalancing its business. It moved toward the Americas, EMEA and Japan, digital marketplaces (Amazon, TikTok Shop) and specialty retail (Sephora, Olive Young-style multi-brand shops), and it used the 2024 consolidation of COSRX as a digital-native growth engine. FY2025 revenue reached KRW 4.25tn (+9.5%) with operating profit of KRW 335.8bn (+52.3%). The TTM to June 2026 reached KRW 4.49tn and KRW 388.5bn. The company targets 10% revenue growth and an operating margin of at least 11% in BY27, and the group targets KRW 15tn of revenue by 2035. --- ### What the company does Amorepacific Corporation develops, manufactures, markets and sells cosmetics (skin care, makeup, fragrance), hair and scalp care, body care and oral care. Under its corporate purpose it also covers household goods and food/health products. The Q1 2026 quarterly report describes its business as cosmetics manufacturing and sales, household goods manufacturing and sales, and food manufacturing and sales (green tea and health functional foods). In practice, revenue is overwhelmingly beauty. For reporting, revenue is split into two business divisions, per S&P Global segment data: **Cosmetics Business Division:** luxury, premium and derma skin care and makeup. KRW 3,794.4bn in FY2025, 89.2% of revenue. **Hair & Beauty (HB) Division:** formerly "Daily Beauty"; hair, scalp, body and oral care. KRW 458.4bn in FY2025, 10.8% of revenue. Management also discloses performance by geography (Domestic vs. Overseas) and within Overseas by region (Americas, EMEA, Greater China, Other Asia including Japan and APAC). In press releases, management emphasises the domestic/overseas axis more than the statutory divisions. ### Business model and revenue model **Revenue model:** almost entirely product sales (consumer packaged beauty goods). There is no material subscription, licensing or service revenue. The revenue mix is therefore effectively 100% product. Minor OEM and other-brand sales are included in "Others" in management IR decks (2025 Korea Conference deck). **Value-chain position:** vertically integrated brand owner. The company runs in-house R&D (Mizium R&D centre, Yongin), in-house manufacturing and logistics (Osan Beauty Park, plus an overseas plant in Shanghai) and brand marketing. Distribution mixes owned and third-party channels. COSRX, consolidated from May 2024, uses a more asset-light model built on digital marketplaces. **Channels (domestic):** e-commerce (own Amoremall plus platforms), multi-brand shops (MBS, chiefly Olive Young-type health & beauty stores), department stores, door-to-door/direct sales ("방판"), duty-free (inbound tourists), cross-border (headquarters supplying overseas distributors and retailers directly) and hypermarkets (declining). **Channels (overseas):** Sephora in the US, Japan and Europe, Amazon (including Premium Beauty), TikTok Shop, Boots (UK), Qoo10 and other Japanese MBS, travel retail (LANEIGE in over 300 overseas duty-free stores excluding Hainan, per Hana, Oct 2026), and mono-brand stores and department stores in Asia. **Customer types:** end consumers via retailers and platforms; B2B sales to distributors and retailers; and wholesale to duty-free operators. **End-markets:** global prestige and masstige skin care, makeup, hair care and personal care. ### Company's own characterisation In its FY2025 results release (6 February 2026), the group frames itself as pursuing leadership in global "beauty and wellness" under the mid- to long-term vision "Create New Beauty." It names five strategic priorities: Everyone Global (core global markets), Holistic (integrated beauty solutions), Ageless (biotechnology-based anti-ageing), AMORE Spark (agile organisation) and AI First (AI-driven work transformation). ### Independent characterisation Amorepacific is a Korean multi-brand beauty house in the late stages of a structural repositioning. From roughly 2010 to 2016 it was a China/duty-free growth story built on luxury skin care (Sulwhasoo) and road-shop masstige (Innisfree, now a sister company under the holding company). The 2017 THAAD dispute, the collapse of Chinese group tourism, the rise of Chinese domestic brands and the ascendancy of Western prestige houses in China drove revenue down from KRW 4.86tn (FY2021) to KRW 3.67tn (FY2023). In 2023 the operating margin fell to 2.9%. Since then the company has (i) bought control of COSRX (digital-native derma brand, over 90% overseas sales), (ii) shifted growth to the Americas, EMEA and Japan, (iii) rebuilt domestic profitability via e-commerce and MBS, and (iv) shrunk and restructured Greater China, which returned to profit in 2025. The result is a more diversified and higher-gross-margin business (72.3% in FY2025 versus 67.7% in FY2022). The operating margin is still below global peers, but the company now runs a credible multi-brand, multi-channel engine. The principal investment debate concerns whether margins can sustainably reach 11–12% while marketing intensity rises to defend share against faster-moving K-beauty challengers such as APR and indie brands.

### Key identifiers | Item | Detail | |---|---| | Legal name | Henkel AG & Co. KGaA | | Legal form | Kommanditgesellschaft auf Aktien (partnership limited by shares); personally liable partner is Henkel Management AG | | Former names | Henkel & Cie (1876); Henkel KGaA (from 1975 conversion until 2008); renamed Henkel AG & Co. KGaA in 2008 (not re-verified) | | Founded | 1876 (Aachen), by Fritz Henkel; 150th anniversary celebrated in 2026 | | Incorporation jurisdiction | Germany (Düsseldorf commercial register) | | Headquarters | Henkelstraße 67, 40589 Düsseldorf, Germany | | Exchanges | Frankfurt (Xetra, regulated market, Prime Standard); also Düsseldorf, Hamburg-Hanover, Munich, Stuttgart, Tradegate BSX (Source: Henkel buyback announcements, Mar 2026) | | Tickers | HEN3 (preferred), HEN (ordinary); US Level-I ADRs: HENKY (preferred), HENOY (ordinary) | | ISIN | Preferred DE0006048432; Ordinary DE0006048408 | | WKN | Preferred 604843; Ordinary 604840 | | CUSIP | Not applicable to the German primary lines; ADR identifiers (e.g., US42550U1097 ADR line cited by finanzen.ch) — full CUSIP set NA | | Fiscal year end | 31 December | | Employees | ~47,000 (FY2025, Henkel); "about 50,000" cited in the H1 2026 release after acquisitions | | Auditor | NA (not re-verified for FY2025 in this review — see Annual Report 2025, auditor's report) | | Market capitalization | ~€31–32bn (both share classes, mid-August 2026; aggregator roic.ai showed €32.37bn at a preferred price of €78.12). A real-time figure as of 7 Oct 2026 was not verifiable in this review | | Index membership | DAX (preferred shares) | | Website | www.henkel.com (IR: www.henkel.com/ir) | | Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |---|---|---|---|---|---| | Employees (approx., thousands, year-end) | NA | NA | NA | 47 | 47 | Note: Henkel describes its workforce as "about 47,000" in FY2024 and FY2025 materials, and "about 50,000" in the H1 2026 release, the step-up reflecting the closed acquisitions (ATP, Wetherby Laroc, Not Your Mother's, OLAPLEX) and the Stahl closing (approx. 1,700 employees) pending at that time. Henkel is a 150-year-old, family-controlled German industrial and consumer group operating two scaled businesses under one listed roof. Adhesive Technologies (≈52% of FY2025 sales, €10.7bn) is, by Henkel's own description, the global leader in adhesives, sealants and functional coatings, anchored by the Loctite, Technomelt, Bonderite and Teroson franchises and deeply embedded in electronics, automotive, packaging, general industry and construction value chains. Consumer Brands (≈47%, €9.7bn) holds leading positions in laundry and home care (Persil, Bref, Pril, Somat) and hair (Schwarzkopf, Syoss, Got2b, and since 2026 OLAPLEX and Not Your Mother's). After a 2022–2025 transformation that merged two consumer units, pruned >€1bn of low-margin sales and lifted group adjusted EBIT margin from 10.4% (2022) to 14.8% (2025), Henkel pivoted in 2026 to acquisitive growth, committing ~€5bn to five deals. The investment case now rests on whether specialty-adhesive and premium-hair compounding can outrun a structurally slow European laundry base. --- ### Company's own description (paraphrased from FY2025/H1 2026 releases) Henkel describes itself as holding leading market positions worldwide in both industrial and consumer businesses through its brands, innovations and technologies. It characterizes Adhesive Technologies as the global leader in adhesives, sealants and coatings, and Consumer Brands as holding leading positions especially in laundry & home care and hair across many markets and categories. It names Loctite, Persil and Schwarzkopf as its three strongest brands, and its corporate purpose as "Pioneers at heart for the good of generations" (Source: Henkel FY2025 news release, 11 Mar 2026; H1 2026 release, 6 Aug 2026). ### Independent characterization Henkel is best understood as two economically distinct businesses sharing a capital allocator, a family shareholder and a balance sheet: **Adhesive Technologies (HAT)** is a specialty-chemicals formulator. It buys commodity and specialty raw materials (polymers, resins, monomers, silicones, solvents, fillers), formulates proprietary chemistries, and sells them predominantly B2B, either as specified, qualified components in customer manufacturing processes (e.g., electronics underfills, battery thermal interface materials, automotive structural adhesives, flexible-packaging laminating adhesives) or via distribution and retail to craftsmen and consumers (Loctite, Pattex, Ceresit, Pritt). Its economics derive from specification lock-in (qualification cycles of 1–3 years in automotive/electronics), technical service intensity, and small cost-in-use share relative to the customer's bill of materials. Margins (adjusted EBIT 16.7% FY2025; 17.7% H1 2026) are structurally higher than the consumer business. **Consumer Brands (HCB)** is an FMCG brand owner selling through mass retail, drugstores, e-commerce and — in Hair Professional — salons and specialty retail. Its economics derive from brand equity, innovation cadence, advertising scale, and retailer negotiating power. Adjusted EBIT margin rose from a combined 8.3% (FY2022, pre-merger perimeter) to 14.5% (FY2025) through ~€525m+ of merger savings, portfolio pruning and "valorization" (mix upgrading). ### Business and revenue model | Dimension | Adhesive Technologies | Consumer Brands | |---|---|---| | Revenue type | Product sales (formulated chemistry); technical service bundled, not separately billed (no disclosed service revenue) | Product sales of branded consumer goods | | Subscription/licensing | Not material / not disclosed | Not material; some brand licensing historically (e.g., Vidal Sassoon China rights acquired 2024 — not re-verified) | | Customer type | OEMs (electronics, auto, packaging converters), industrial MRO, distributors, DIY/retail, professional craftsmen | Retailers (grocery, drugstore, mass, club), e-commerce, salons/specialty retail (Hair Professional) | | Value-chain position | Mid-stream specialty formulator between petrochemical suppliers and manufacturers | Downstream brand owner/manufacturer | | Pricing power | Moderate-high (low cost share, specification lock-in) | Moderate (brand-dependent; retailer power; private-label competition) | | Cyclicality | Industrial-cyclical (auto, electronics, construction, packaging volumes) | Defensive but elastic to consumer down-trading | ### End-markets served Electronics (semiconductor packaging, consumer devices, data-center/AI hardware, displays); automotive and e-mobility (structural bonding, battery assembly, thermal management, ADAS sensors); general industry and MRO (threadlockers, gasketing, surface treatment, industrial coatings, protective coatings for infrastructure via Seal For Life); packaging and consumer goods (flexible packaging, labels, paper/board, hygiene, metal-packaging sealants under Darex); construction (tile adhesives, façade/ETICS systems, waterproofing — Ceresit, Wetherby Laroc); craftsmen/DIY; and — via Stahl from Oct 2026 — coatings for flexible materials (leather, synthetic leather, textiles) serving automotive interiors, fashion/lifestyle and packaging. Consumer end-markets: fabric cleaning, fabric finishers, fabric care, dishwashing, surface and toilet care, air care; hair colorants, care, styling and professional salon; body care (soaps, shower gels — Dial, Fa); and residual oral/skin care.

Beiersdorf is a Hamburg-based, family-controlled skin care specialist with €9.85 billion of sales and a net cash balance sheet. Its Consumer segment (83% of sales) is built on NIVEA, the mass-market brand that still generates about two-thirds of Consumer revenue, alongside a fast-growing dermocosmetics franchise (Eucerin, Aquaphor), a wound-care business (Hansaplast, Elastoplast) and luxury skin care (La Prairie, Chantecaille). The tesa segment (17% of sales) is an independently managed adhesive-technology business serving electronics, automotive and consumer markets. The company's edge is proprietary skin science, notably the patented actives Thiamidol and Epicelline, which has driven five consecutive years of double-digit Derma growth. Its weakness is concentration: NIVEA's sales fell 6.8% organically in the first half of 2026, forcing a profit warning and an 18-month turnaround plan. Beiersdorf is therefore a high-quality balance sheet attached to a two-speed portfolio, with the equity story now dependent on restoring NIVEA volume growth. Third-party services quoted the market capitalization between €16.35 billion and €16.9 billion in the same week, depending on price date and on whether treasury shares are excluded. The company's own convention since 2024 excludes treasury shares. --- **Company's own description.** Beiersdorf describes itself as a company that has stood for innovative skin care and pioneering skin research for over 140 years, headquartered in Hamburg and employing more than 22,000 people (Q1 26 statement boilerplate). The Annual Report states that the Group operates two business segments, Consumer and tesa, with tesa managed since 2001 as an independent sub-group (AR 2025; Beiersdorf AG Annual Financial Statements 2025). **Independent characterization.** Beiersdorf is best understood as three businesses with different economics sharing one balance sheet. 1. A mass-market skin and personal care business (NIVEA, Labello, 8x4, Hidrofugal and local brands). It sells through grocery, drugstore and e-commerce channels, competes on brand trust and price accessibility, and is exposed to retailer negotiations and private label. 2. A science-led premium business (Derma, Health Care, Luxury). It is sold through pharmacies, dermatologist recommendation, department stores, travel retail and e-commerce, with pricing power derived from patented actives and clinical claims. 3. An industrial technology business (tesa). It sells engineered adhesive tapes and systems to electronics, automotive, printing and building customers on a specification basis, plus a consumer and craftsmen tape range. **Revenue model.** Revenue is almost entirely product sales recognised on transfer of goods. There is no material subscription or service revenue. Beiersdorf AG, the parent, additionally earns intra-group royalty and dividend income from affiliates (AR 2025, Beiersdorf AG section), but this eliminates on consolidation. Licensing to third parties is not disclosed as a material revenue line. **Value chain position.** Beiersdorf is a brand owner and manufacturer. It runs its own research (1,849 R&D employees per AR 2025), formulates and produces most volume in its own plants, and sells to retailers, pharmacies, distributors and industrial customers. It does not own retail except selective La Prairie counters and direct e-commerce. **Customers and end-markets.** **Sales mix (FY2025, FY25 release).** Consumer €8,176 million (83.0%), tesa €1,676 million (17.0%). By region: Europe 44.1%, Africa/Asia/Australia 30.4%, Americas 25.4% (AR 2025 FAQ).

A three-year employee trend is not publicly disclosed. The aggregator figures suggest growth from about 80 in 2017 to somewhere above 100 by 2025, but the sources use different methods and should not be read as a series. Bedoukian Research is a small, family-owned US maker of high-impact aroma chemicals, founded in 1972 and based in Danbury, Connecticut. It does not compete with the large flavor and fragrance houses in compounding. It sells single molecules to them and to other formulators: unsaturated aldehydes, leaf-alcohol derivatives, lactones, jasmonoids and similar materials that work at low dose. A second brand, BedoukianBio, applies the same multi-step organic synthesis to insect pheromones and repellent actives. A third activity is custom and toll manufacturing for pharmaceutical, biotech and agrochemical clients. The company's edge is chemistry depth and speed: R&I reports directly to the CEO and sits next to the plant. Its constraints are scale, a single manufacturing site and limited disclosure. Since the death of long-time president Dr. Robert Bedoukian in August 2024, the company has moved to professional management, appointing a non-family CEO in October 2025. --- **The company's own description.** There is no annual report. The closest equivalent is the boilerplate in the 18 May 2026 press release, which describes a family-owned specialty chemical company founded in 1972 and headquartered in Danbury. It supplies aroma chemicals and blends for flavor, fragrance and personal care under the Bedoukian Flavor & Fragrance brand, and provides custom manufacturing for pharmaceutical, biotech and agrochemical clients. The October 2025 CEO announcement adds semiochemicals as a second served industry alongside flavor and fragrance. **Independent characterization.** Bedoukian is an upstream ingredient manufacturer. It sits between commodity and fine-chemical feedstock suppliers and the compounders (flavor and fragrance houses) that blend ingredients into finished flavors and perfumes for consumer goods companies. Its catalog is weighted to "high-impact" molecules, meaning materials used at fractions of a percent in a formula. The 2026 featured fragrance list shows recommended odor evaluation levels of 0.1% to 10%. This positions the company in low-volume, high-value specialties, where purity, isomer control and reliable supply matter more than tonnage. **Revenue model.** All evidence points to product sales (merchant sale of molecules by the kilogram) plus fee-based custom synthesis and toll processing. There is no indication of subscription or licensing revenue. Repellent actives are patented and offered as ingredients for others' formulations, which could involve licensing, but no licence terms are disclosed. The revenue mix across flavor, fragrance, pheromones and custom work is not publicly disclosed. **Value chain position.** **End-markets.** Per the company: food and beverage flavors, fine fragrance, personal care, home care and air care; agricultural, forestry, residential and stored-product pest management through BedoukianBio; and pharmaceutical, biotech, agrochemical and specialty chemical custom manufacturing. **Catalog size: conflicting figures.** Sources differ and the discrepancy should be noted, not resolved by guesswork: The differences probably reflect definitions (all catalog items versus actively promoted molecules), but this is not confirmed.

| Field | Detail | |---|---| | Entity profiled | Reckitt Benckiser Group plc (trading name "Reckitt"). This is the exact legal-name match. | | Listing status | Public company, confirmed. Listed on the London Stock Exchange Main Market and a FTSE 100 constituent. This matches the type supplied. | | Former names / predecessors | Reckitt & Colman plc and Benckiser N.V. merged in December 1999 to form Reckitt Benckiser plc. Reckitt Benckiser Group plc became the group holding company in a 2007 reconstruction. The corporate brand was changed to "Reckitt" in March 2021. | | Founding | Benckiser roots date to 1823 (Germany). Reckitt & Sons dates to 1840 (Hull, England). The current group was formed in 1999. | | Incorporation jurisdiction | England and Wales (UK) | | Companies House number | 06270876 (from prior knowledge; not re-verified this cycle) | | LEI | 5493003JFSMOJG48V108 | | Registered office / HQ | 103–105 Bath Road, Slough, Berkshire SL1 3UH, United Kingdom (H1 2026 Statement, Note 1) | | HQ discrepancy | Some 2026 press (Alliance News, Q1 2026 coverage) describes the company as "Uxbridge-based". Company filings still cite Slough as the registered office. | | Primary listing / ticker | LSE: RKT | | Other lines | US OTC ADR: RBGLY. US OTC ordinary line: RBGPF. Xetra/Frankfurt: 3RB. Mexican BMV: RB N. | | ISIN | GB00BSZBP530. This is the new ISIN from 2 February 2026, after the 24-for-25 share consolidation. The old ISIN was GB00B24CGK77 (Eurex corporate action notice, Jan 2026). | | CUSIP (ADR) | — | | Nominal value per share | 10 5/12 pence after the consolidation (H1 2026, Note 9) | | Shares in issue | 674,005,752 at 30 Jun 2026, of which 38,950,759 were held in treasury (H1 2026, Note 9). Voting shares were therefore about 635.1m before H2 2026 buybacks. | | Fiscal year end | 31 December | | Auditor | KPMG LLP. In H1 2026 the Board decided to retain KPMG and not proceed with the previously announced move to PwC (H1 2026 Statement). | | Website | www.reckitt.com | | Measure | Value | Source | |---|---|---| | Latest (company) | About 36,000 employees in 80 countries | reckitt.com homepage, 2026, after the Essential Home divestment | | Third-party (Revelio Labs, modelled) | About 43,000 (2023), about 41,700 (2024), about 41,400 (2025) | Revelio Labs, Sep 2025 | | Other aggregators | 35,139 (Morningstar); 37,900 (MarketScreener) | — | The three-year trend is down. Headcount fell from roughly 40,000+ before the July 2024 strategy reset to about 36,000 after the Essential Home carve-out. Drivers were the transfer of six plants and their staff to Advent, management-layer reduction under Fuel for Growth (five layers cut to three), and shared-service consolidation. ### Market capitalisation | Measure | Value | Source | |---|---|---| | Share price | 4,905p (25 Sep 2026 close) | StockAnalysis | | Market cap (implied) | About £31.1bn, using about 635m voting shares | Derived | | Market cap (secondary) | £32.6bn on 28 Aug 2026 at 5,132p | StockAnalysis | | Enterprise value | About £40.5bn | Market cap plus H1 2026 net debt of £9,380m | Reckitt is a UK-headquartered, pure-play consumer health and hygiene company that is part-way through a deliberate portfolio contraction. It owns 11 "Powerbrands" that drive more than 80% of Core net revenue: Dettol, Lysol, Harpic, Finish, Vanish, Durex, Veet, Mucinex, Nurofen, Strepsils and Gaviscon. Since the July 2024 strategy update, Reckitt has done the following: - sold a 70% stake in its £1.9bn-revenue Essential Home household business to Advent International (completed 31 December 2025); - returned £6.4bn to shareholders since July 2024; - cut fixed costs from 20.9% to 19.4% of revenue in one year; - reclassified Mead Johnson Nutrition (£2.1bn revenue) as non-core, with all options open. Core Reckitt grew 5.2% LFL in 2025, at a 26.7% adjusted operating margin. Emerging Markets are now its largest area at 44% of Core revenue in H1 2026. The investment case rests on three things: medium-term 4–5% Core growth, margin expansion, and a clean exit from Mead Johnson. That exit is weighed down by US NEC litigation, although the defence record has recently been strong. --- ### What the company does | Unit | Contents | Share of revenue | |---|---|---| | Core Reckitt | Four product categories (Self Care, Germ Protection, Household Care, Intimate Wellness), managed through three geographic Areas (Emerging Markets, Europe, North America) | 80% of H1 2026 Group revenue | | Mead Johnson Nutrition (MJN) | Infant and child nutrition (Enfamil, Nutramigen). Designated non-core. | 17% of H1 2026 Group revenue | | Vestacy Transitional Services | Low-margin transitional manufacturing and distribution for the divested Essential Home business, now named Vestacy. Expected to run off as separation completes. | £235m revenue in H1 2026 at about 5% gross margin | Reckitt develops, manufactures, markets and sells branded consumer health and hygiene products. Its own description of its purpose is to "protect, heal and nurture in the pursuit of a cleaner, healthier world" (company boilerplate, 2025–26 RNS). In its July 2024 Strategy Update and the FY2024/FY2025 reports, management set the ambition to become a "world-class consumer health and hygiene company" focused on high-growth, high-margin Powerbrands. From 1 January 2026, reported operations are: ### Business and revenue model | Revenue type | Approximate mix | Comment | |---|---|---| | Branded product sales: OTC health, VMS, sexual wellness, hygiene, household | About 96% of H1 2026 Group revenue | Core Reckitt plus MJN | | Transitional services and contract manufacturing (Vestacy) | About 4% of H1 2026 Group revenue | Declining. Very low margin. | | Subscription / licensing | Not material; not separately disclosed | n/a | Reckitt's revenue is almost entirely product sales of branded fast-moving consumer goods (FMCG) and over-the-counter (OTC) medicines. It has: - no material subscription revenue; - no material licensing revenue. Minor brand-licensing income exists in some markets; not separately disclosed. - a small service-type income stream from 2026: transitional manufacturing, distribution and services income from Vestacy (£248m of related-party income in H1 2026 under IAS 24); - vendor loan note interest (£10m in H1 2026); - a share of the Vestacy associate's result (a £23m loss in H1 2026). ### Value-chain position Reckitt is a vertically integrated brand owner. It handles: - R&D, including medical and material science; - regulatory affairs for OTC drugs and infant formula, which are FDA-regulated in the US; - in-house manufacturing across a global plant network, supplemented by co-manufacturers; - brand marketing (Brand Equity Investment was 14.6% of net revenue in FY2025); - sales and distribution to retail customers. It does not own retail. It sells through: - mass grocery and hypermarkets; - drugstores and pharmacies; - e-commerce, which is material in China, where social e-commerce and new online launches drive growth; - traditional trade (kiranas) in India and other emerging markets; - hospital and clinical channels for MJN preterm products and for Biofreeze clinical sales. ### Customer types and end-markets | Customer type | Channel examples | Exposure | |---|---|---| | Mass retailers and grocers | Walmart, Target, Tesco and other major multiples (named retailers not disclosed by share) | Hygiene and household brands | | Pharmacy and drug chains | US drug chains, European pharmacies | Self Care OTC: Mucinex, Nurofen, Strepsils, Gaviscon | | E-commerce platforms | Amazon, Tmall/JD, Douyin and other social commerce | High share in China (Durex, Intima, Move Free, Dettol) | | Traditional trade | India and Africa distributor networks | Dettol, Harpic, Durex | | Healthcare professionals and hospitals | NICUs, paediatricians, clinics | MJN preterm and specialty formulas; Biofreeze clinical | | Governments and programmes | US WIC (Women, Infants and Children) programme contracts | MJN; WIC shipments are lower value per unit | End-markets served: - consumer OTC healthcare (cold and flu, pain, digestive health); - vitamins, minerals and supplements (VMS); - sexual wellness and intimate care; - hair removal; - surface and personal disinfection; - toilet care; - automatic dishwashing; - laundry stain removal; - infant and specialised paediatric nutrition. ### Independent characterisation Reckitt is best understood as a two-speed consumer-health hybrid. Roughly half of Core revenue sits in OTC and VMS ("Self Care") and sexual wellness. These are structurally higher-growth and higher-margin categories with pharmacy-like regulatory moats. The other half sits in hygiene and household categories (Germ Protection and Household Care). These carry strong brand shares but face private-label and promotional pressure, especially autodish in Europe. The 2024–2026 programme has three parts: - removing the lowest-growth home-care tail (Essential Home); - ring-fencing the litigated nutrition asset (MJN); - funding brand investment through fixed-cost reduction. The mix shift toward Emerging Markets is pronounced. Emerging Markets delivered LFL growth of 14.6% in FY2025 and 8.5% in H1 2026, which makes the group more growth-geared but also more exposed to FX, geopolitical shocks (Middle East, Russia) and Chinese tax and regulatory changes such as the VAT on condoms.

Canon Inc. is a ¥4.6 trillion Japanese technology conglomerate. Its roots are in optics and precision engineering, which it has extended into four industry-facing groups: Printing, Medical, Imaging and Industrial. Office and production printing still provide more than half of revenue and most of the cash flow. Growth now comes from mirrorless and network cameras, diagnostic imaging, and a semiconductor-equipment franchise that has gained strategic weight as AI-driven memory and advanced-packaging investment rises. In semiconductor manufacturing, Canon is the world's leading supplier of i-line lithography steppers and a major KrF scanner vendor. It also makes FPD lithography systems, OLED evaporation lines (Canon Tokki), sputtering and deposition tools (Canon Anelva) and die bonders. It is commercialising nanoimprint lithography (NIL) as a lower-cost path to leading-edge patterning. Canon also supports the installed base of its steppers through refurbishment, relocation and spare-parts programmes, which place it squarely in the semiconductor equipment refurbishment ecosystem. Founder-era continuity remains distinctive: Fujio Mitarai has led the company for most of the past three decades. Under the Phase VII plan (2026–2030), management is pursuing productivity-led growth toward ¥5.6 trillion of sales and a 15% operating margin by 2030. --- ### What the company does Canon designs, manufactures, sells and services imaging, printing, medical and industrial equipment worldwide. The FY2025 Annual Securities Report organises the business into four reportable segments plus "Others and Corporate": **Printing:** digital continuous-feed and sheet-fed production presses, large-format printers, office multifunction devices (MFDs), laser and inkjet printers, image scanners and calculators. **Medical:** CT, MRI, diagnostic ultrasound, diagnostic X-ray, digital radiography, ophthalmic equipment, in-vitro diagnostic systems and reagents, and healthcare IT. **Imaging:** interchangeable-lens and compact digital cameras, interchangeable lenses, network cameras, video-management and video-analytics software, camcorders, cinema cameras and broadcast equipment. **Industrial:** semiconductor lithography equipment, FPD lithography equipment, OLED display manufacturing equipment, vacuum thin-film deposition equipment and die bonders. **Others and Corporate:** handy terminals, document scanners and other businesses, including the space business developed through Canon Electronics. ### Business and revenue model Canon's model combines hardware sales with recurring revenue, and the mix differs sharply by segment: **Printing:** is a classic installed-base model. Device placements (MFDs, laser printers, inkjet printers, production presses) generate long-tail revenue from toner, ink, maintenance contracts, managed print services and document-workflow software. Consumables and service ("non-hardware") are the main profit pool. Sell-in of hardware is the leading indicator of future annuity revenue. **Medical:** sells capital equipment (CT, MRI, ultrasound, X-ray) to hospitals and imaging centres, mostly built to order, together with multi-year service contracts, IVD reagents and healthcare IT. **Imaging:** is mainly product sales: camera bodies, lenses and network cameras. A growing software and licence layer comes through Axis (network video) and Milestone Systems (video management software, VMS). **Industrial:** sells capital equipment to semiconductor, display and electronics manufacturers. Lithography revenue depends on unit shipments and mix (KrF scanners sell at higher prices than i-line steppers), followed by installation, field service, spare parts, upgrades and refurbishment over each tool's multi-decade life. Canon does not publish a formal split of product, service, subscription and licensing revenue. Its own commentary consistently treats consumables, maintenance and services in Printing, and service contracts in Medical, as the core of recurring revenue. Intellectual property also produces licensing income: Canon ranked seventh worldwide by U.S. patents granted in 2025, with 2,623 patents. ### Value-chain position Canon is unusually vertically integrated. It develops and makes its own optical glass and lenses, CMOS image sensors, inkjet printheads, toner, and many key components and production machines (the latter through Canon Semiconductor Equipment Inc. and other units). In semiconductors it is an equipment supplier (Tier 1 tool OEM) to chipmakers and to OSATs and advanced-packaging houses. It is not a chip producer for third parties, although it makes sensors for its own products. ### Customer types and end-markets | Segment | Principal customers | End-markets served | |---|---|---| | Printing | Corporates, SMBs, governments, print service providers, publishers, packaging converters, consumers | Office document output, commercial and transactional printing, book printing, signage and graphics, home printing | | Medical | Hospitals, clinics, imaging centres, laboratories, research institutes | Diagnostic imaging, in-vitro diagnostics, healthcare IT | | Imaging | Consumers, creators, professional photographers, broadcasters, cinema producers, security integrators, municipalities, retailers | Consumer and professional photography, video and cinema, physical security and video analytics | | Industrial | Memory, logic, power, sensor and MEMS chipmakers; OSATs; display panel makers; electronics manufacturers | Front-end semiconductor lithography, advanced packaging, FPD lithography, OLED deposition, thin-film deposition (including HBM-related), die bonding | **Printing:** Principal customers: Corporates, SMBs, governments, print service providers, publishers, packaging converters, consumers; End-markets served: Office document output, commercial and transactional printing, book printing, signage and graphics, home printing **Medical:** Principal customers: Hospitals, clinics, imaging centres, laboratories, research institutes; End-markets served: Diagnostic imaging, in-vitro diagnostics, healthcare IT **Imaging:** Principal customers: Consumers, creators, professional photographers, broadcasters, cinema producers, security integrators, municipalities, retailers; End-markets served: Consumer and professional photography, video and cinema, physical security and video analytics **Industrial:** Principal customers: Memory, logic, power, sensor and MEMS chipmakers; OSATs; display panel makers; electronics manufacturers; End-markets served: Front-end semiconductor lithography, advanced packaging, FPD lithography, OLED deposition, thin-film deposition (including HBM-related), die bonding ### Independent characterisation Canon is best understood as a cash-generative printing annuity that funds a portfolio of optical-technology growth businesses. Three of those businesses now matter most to the investment case. Network video (Axis/Milestone) is structurally growing. Medical imaging is a turnaround: Canon took a ¥165.1 billion goodwill impairment in FY2024 and then folded Canon Medical Systems into the parent company in April 2026. Semiconductor lithography is small in revenue terms (Industrial was 7.8% of FY2025 sales) but very profitable and strategically valuable, because Canon supplies the mature-node i-line and KrF tools that memory, power, image-sensor and advanced-packaging fabs need in volume. Canon also runs refurbishment programmes for its own photolithography tools, which keeps its legacy installed base (for example the FPA-3000 series) productive in 150 mm and 200 mm fabs. That puts Canon in direct competition with third-party refurbishers such as Ventex in the semiconductor-equipment refurbishment services market.